1501 / 1835
ECHELON-1 Highlights
• Improved treatment of FL HL would represent significant progress in an indication where
treatment options have changed little in > 20 yrs
• Evaluation of brentuximab vedotin as a replacement for bleomycin in the AVD
combination regimen is hypothesized to provide an improvement in PFS over the
standard ABVD regimen, and eliminate the risk of bleomycin-associated pulmonary
toxicity.
• Approximately 1040 patients at ~200 sites will be randomized to receive either A+AVD or
ABVD; enrollment began in late 2012